19 results about "Mimotope" patented technology

Provided herein are methods for discovering and optimizing lasso peptides using an integrated and iterative workflow involving structure-based design principles, in silico modeling, epitope grafting, virtual screening, genetic engineering, peptide evolution, and experimental testing. Also provided herein are lasso peptides that have been discovered and optimized for binding selectivity, binding affinity, biological activity, and other properties using the methods described herein.

The present invention belongs to the technical field of phage display peptide libraries, and specifically relates to a diethylstilbestrol mimotope peptide, a preparation method thereof and an application. The amino acid sequence of the antigen mimotope peptide of diethylstilbestrol is YVYPQMP. When applied, the antigen mimotope can be used for immunological detection by biologically synthesizing the antigen mimotope peptide, or the phage displaying the diethylstilbestrol mimotope can be directly obtained through phage amplification for immunoassay, or the diethylstilbestrol mimotope can be separated from the phage to replace the diethylstilbestrol standard for immunological detection and analysis. The detection process is simple and convenient, the result is accurate, and the sensitivity is high. The present invention effectively improves the detection sensitivity of diethylstilbestrol in food, and at the same time reduces the harm to the human body and the ecological environment during the detection process of diethylstilbestrol, and has outstanding application value.

Disclosed herein are mimotopes, engineered protease activatable receptors (PARs), immune cells including said engineered PARs and reporter nucleic acids encoding reporter molecules which can be secreted by said immune cells, and methods of detecting cancer using the same.

Described herein are methods of treating a human child including administering to the human child a compound selected from epigallocatechin gallate (EGCG), or a derivative thereof selected from epicatechin (EC), epigallocatechin (RGC) and epicatechin gallate (ECG), sulforaphane, olive oil, phylloquinone, quercetin, safranal, hydroxtyrosol, menaquinone-4, menaquinone-7, oleocanthal, peptide Ins-1 B9-23 19CAM22R-E, peptide Ins-1 B12-23-19CAM, peptide Ins-1 B12-23 19CAM22R-E, or a combination of any of the foregoing, wherein administration of the treatment is started between birth and six months of age. Also described are methods of treating a pregnant human or a nursing human mother who has recently given birth to an infant. Further described are insulin B chain mimotope peptides.

Compositions and methods are provided for peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.

A vaccine composition for immunizing and / or protecting a mammal against an IL-31 mediated disorder is provided, wherein the composition includes: the combination of a carrier polypeptide and at least one mimotope selected from a feline IL-31 mimotope, a canine IL-31 mimotope, a horse IL-31 mimotope, and a human IL-31 mimotope; and an adjuvant. Such vaccines can be in the form of pharmaceutical compositions useful for treating or protecting mammals such as cats, dogs, horses, or humans against IL-31-mediated disorders.

Disclosed herein are compositions and methods for predicting or assessing the presence and / or severity of IgE-mediated peanut allergy in a subject using peptides and or mimotopes that bind as well or better than naturally occurring sequences. The disclosed methods and compositions may comprise one or more peptides or mimotopes of Ara h 2, specifically Epitope 3, or a portion thereof. In many embodiments, the peptides and mimotopes may comprise at least one DPY_P sequence, and in many cases the second proline, “P,” in the sequence may be hydroxylated (i.e. “h”) and may be represented by h. In many embodiments, substituting a P->h within the disclosed peptide and mimotope sequences may increase binding of IgE from the subject. In many embodiments, enhanced binding of IgE from a subject indicates that the subject suffers from an IgE-mediated peanut allergy.

The application discloses a fengycin mimotope peptide which can be specifically combined with fengycin antibody, and a sensitive and rapid competitive enzyme-linked immunoassay method can be established by using the phage displaying the mimotope peptide or the mimotope peptide. 50 The IC50 is 0.30 ng / mL, and the LOD is 0.02 ng / mL, and the sensitivity of the method is improved by 60 times compared with the sensitivity of a traditional enzyme-linked immunoassay method based on a hapten; the competitive immunoassay method based on the mimotope peptide has good cross reactivity to other common structural analogues.

The disclosure provides for covalent dual-functional inhibitors of peanut allergic reactions where the inhibitors include a targeting moiety comprising a peanut allergen protein epitope or mimotope peptide sequence, a reactive functional group capable of forming a site-directed covalent bond to the amine moiety of a lysine amino acid of an allergen reactive immunoglobulin, and a variable length spacer comprising oligomers of ethylene glycol monomers, amino acids, saccharides, hydrocarbons, fluorinated hydrocarbons, or a combination thereof, wherein the 10 spacer is conjugated by one or more amide bonds to the TM and the FG.

The present invention provides peptides that specifically bind to maternal autoantibodies that are generated in the mother or potential mother against one or more endogenous polypeptide antigens selected from lactate dehydrogenase A (LDH A), lactate dehydrogenase B (LDH B), stress-induced phosphoprotein 1 (STIP1), guanine deaminase (GDA), Y Box Binding Protein 1 (YBX1), collapsin response mediator protein 1 (CRMP1), and collapsin response mediator protein 2 (CRMP2). The peptides described herein are useful for determining a risk of an offspring for developing an autism spectrum disorder (ASD) by detecting the presence of maternal autoantibodies in a biological sample of the mother or potential mother. The peptides or mimotopes thereof can also be administered to the mother or potential mother to block the binding between maternal autoantibodies and their antigens, thereby neutralizing the maternal autoantibodies.

The invention relates to an okadaic acid mimic epitope peptide and application. The amino acid sequence of the okadaic acid mimic epitope peptide is shown as SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 15. The mimic epitope peptide can be specifically combined with an okadaic acid antibody, and a sensitive and rapid competitive enzyme-linked immunosorbent assay is established by using the phage for displaying the mimic epitope peptide; according to the method, the IC50 is 0.83 ng / mL, the LOD is 0.21 ng / mL, and the detection range is 0.35 to 1.98 ng / mL; the competitive immunoassay method established on the basis of the mimic epitope peptide provided by the invention is more sensitive than the traditional immunoassay method, has good cross reaction to other marine toxins, avoids the use of toxin antigens, and is green and environment-friendly.

Disclosed are a peptide having CGRP mimotope function and CGRP detection using same. The peptide may have the following sequences: DVGSYTKAPDF, YGPGGSQAVDF, CRARAGIGLDF, and YVAKATGPADF. The peptide of the present invention can be used in a rapid and accurate single-step immunoassay for CGRP detection, and thus can be effectively used for diagnosis and treatment monitoring of migraine patients.

The present disclosure relates generally to compositions and methods for improving the safety of adoptive immune cell therapy, including the use of a depletion tag (e.g., an epitope or a mimotope) that is capable of being bound by another molecule (e.g., an antibody) to facilitate the depletion of the engineered immune cells. One class of depletion tags disclosed herein contain an epitope or mimotope derived from a biomarker of a hematologic cancer (e.g., CCR4). A second class of depletion tags disclosed herein contain an epitope or mimotope derived from the same antigen that the engineered receptor binds to (e.g., a DLL3 derived depletion tag for engineered immune cells that bind to DLL3).

Provided herein are self-assembling peptide amphiphiles (PAs) comprising a bioactive Transforming growth factor beta 1 (TGF-β1) mimetic epitope, high-aspect-ratio nanostructures of PAs displaying a TGF-β1 mimetic epitope, and methods of enhancing cartilage regeneration / repair and / or treatment of osteoarthritis and other musculoskeletal injuries and diseases.

The present invention application discloses a BoHV-1 virus antigenic epitope polypeptide, its conjugate protein, an enzyme-linked immunosorbent assay kit and applications thereof, aiming to solve the technical problems of the scarcity of BoHV-1 virus immune kits, complex preparation processes and high costs. The present invention application first screens for dominant mimotopes using a phage library and BoHV-1 virus polyclonal antiserum; subsequently synthesizes corresponding polypeptides to identify the dominant B cell epitopes of the virus, and further screens for B cell epitopes suitable for antibody preparation; finally, develops an ELISA kit for detecting BoHV-1 virus based on the B cell epitopes. The B cell epitope polypeptide provided by the present invention application has high specificity and sensitivity, and the provided enzyme-linked immunosorbent assay kit has high specificity and good detection performance.

The present disclosure relates generally to compositions and methods for improving the safety of adoptive immune cell therapy, including the use of a depletion tag (e.g., an epitope or a mimotope) that is capable of binding to another molecule (e.g., an antibody) to facilitate the depletion of the engineered immune cells. One class of depletion tags disclosed herein contain an epitope or mimotope derived from a biomarker of a hematologic cancer (e.g., CCR4). A second class of depletion tags disclosed herein contain an epitope or mimotope derived from the same antigen that the engineered receptor binds to (e.g., a DLL3 derived depletion tag for engineered immune cells that bind to DLL3).

The present disclosure relates generally to compositions and methods for improving the safety of adoptive immune cell therapy, including the use of a depletion tag (e.g., an epitope or a mimotope) that is capable of being bound by another molecule (e.g., an antibody) to facilitate the depletion of the engineered immune cells. One class of depletion tags disclosed herein contain an epitope or mimotope derived from a biomarker of a hematologic cancer (e.g., CCR4). A second class of depletion tags disclosed herein contain an epitope or mimotope derived from the same antigen that the engineered receptor binds to (e.g., a DLL3 derived depletion tag for engineered immune cells that bind to DLL3).

Disclosed herein are mimotopes, engineered protease activatable receptors (PARs), immune cells including said engineered PARs and reporter nucleic acids encoding reporter molecules which can be secreted by said immune cells, and methods of detecting cancer using the same.

The present invention provides a method of determining the identity and / or amount of an anti-IL-31 antibody in a sample. Such a method includes incubating a sample comprising an anti-IL-31 antibody with at least one mimotope selected from a feline IL-31 mimotope, a canine IL-31 mimotope, a horse IL-31 mimotope, and a human IL-31 mimotope; and determining the identity and / or quantity of the anti-IL-31 in the sample.